These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1568412)

  • 41. Tumour associated antigens in diagnosis of serous effusions.
    Mezger J; Permanetter W; Gerbes AL; Wilmanns W; Lamerz R
    J Clin Pathol; 1988 Jun; 41(6):633-43. PubMed ID: 2454957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Can carcinoma cells in ascitic and pleural effusions be reliably identified by immunocytochemical detection of "panepithelial antigens" EMA, egp34, BW-495 and TAG-72?].
    Mezger J; Stötzer O; Schilli G; Bauer S; Wilmanns W
    Pathologe; 1991 Jan; 12(1):30-4. PubMed ID: 2023891
    [No Abstract]   [Full Text] [Related]  

  • 43. Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions.
    Zimmerman RL; Fogt F; Goonewardene S
    Cancer; 2000 Aug; 90(4):230-4. PubMed ID: 10966563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunocytochemical reaction of Ca1 and HMFG2 monoclonal antibodies with cells from serous effusions.
    Singer S; Boddington MM; Hudson EA
    J Clin Pathol; 1985 Feb; 38(2):180-4. PubMed ID: 3881482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Malignant effusions: from diagnosis to biology.
    Davidson B
    Diagn Cytopathol; 2004 Oct; 31(4):246-54. PubMed ID: 15452897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
    Pomjanski N; Motherby H; Buckstegge B; Knops K; Rohn BL; Böcking A
    Anal Quant Cytol Histol; 2001 Apr; 23(2):151-60. PubMed ID: 11332082
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
    Rehnberg J; Zendehrokh N; Dejmek A
    Anal Quant Cytol Histol; 2007 Aug; 29(4):217-20. PubMed ID: 17879629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G; Gückel B; Wallwiener D; Moldenhauer G
    Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells.
    Yao X; Labelle M; Lamb CR; Dugan JM; Williamson CA; Spencer DR; Christ KR; Keating RO; Lee WD; Paradis GA; Begum S; Hynes RO; Wittrup KD
    Int J Cancer; 2013 Dec; 133(12):2925-33. PubMed ID: 23775727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor microenvironment: what can effusions teach us?
    Kassis J; Klominek J; Kohn EC
    Diagn Cytopathol; 2005 Nov; 33(5):316-9. PubMed ID: 16240401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies.
    Flynn MK; Johnston W; Bigner S
    Acta Cytol; 1993; 37(4):439-47. PubMed ID: 8328236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic utility of sialosyl-Tn in discriminating carcinomatous cells from benign mesothelium in body cavity effusions.
    Zimmerman RL; Fogt F; Bibbo M
    Acta Cytol; 1999; 43(6):1079-84. PubMed ID: 10578981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utility of tumour markers in the diagnosis of neoplastic pleural effusion.
    San Jose ME; Alvarez D; Valdes L; Sarandeses A; Valle JM; Penela P
    Clin Chim Acta; 1997 Sep; 265(2):193-205. PubMed ID: 9385461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of immunologic tumor markers in body fluid analysis.
    Kjeldsberg CR; Marty J
    Clin Lab Med; 1985 Jun; 5(2):233-64. PubMed ID: 3896624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.
    Ascoli V; Bosco D; Carnovale Scalzo C
    Pathologica; 2011 Dec; 103(6):318-24. PubMed ID: 22558888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions.
    Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
    Acta Cytol; 2010; 54(3):277-82. PubMed ID: 20518411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytomorphological and immunocytochemical study of non-Hodgkin's lymphoma in pleural effusion and ascitic fluid.
    Das DK; Al-Juwaiser A; George SS; Francis IM; Sathar SS; Sheikh ZA; Shaheen A; Pathan SK; Haji BE; George J; Kapila K
    Cytopathology; 2007 Jun; 18(3):157-67. PubMed ID: 17488258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.